These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

361 related articles for article (PubMed ID: 15540247)

  • 1. Prostate carcinoma incidence in relation to prediagnostic circulating levels of insulin-like growth factor I, insulin-like growth factor binding protein 3, and insulin.
    Chen C; Lewis SK; Voigt L; Fitzpatrick A; Plymate SR; Weiss NS
    Cancer; 2005 Jan; 103(1):76-84. PubMed ID: 15540247
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum insulin-like growth factor I: tumor marker or etiologic factor? A prospective study of prostate cancer among Finnish men.
    Woodson K; Tangrea JA; Pollak M; Copeland TD; Taylor PR; Virtamo J; Albanes D
    Cancer Res; 2003 Jul; 63(14):3991-4. PubMed ID: 12873996
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Insulin-like growth factors and prostate cancer: a population-based case-control study in China.
    Chokkalingam AP; Pollak M; Fillmore CM; Gao YT; Stanczyk FZ; Deng J; Sesterhenn IA; Mostofi FK; Fears TR; Madigan MP; Ziegler RG; Fraumeni JF; Hsing AW
    Cancer Epidemiol Biomarkers Prev; 2001 May; 10(5):421-7. PubMed ID: 11352850
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High levels of circulating insulin-like growth factor-I increase prostate cancer risk: a prospective study in a population-based nonscreened cohort.
    Stattin P; Rinaldi S; Biessy C; Stenman UH; Hallmans G; Kaaks R
    J Clin Oncol; 2004 Aug; 22(15):3104-12. PubMed ID: 15284261
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Circulating insulin-like growth factor-I and binding protein-3 and risk of prostate cancer.
    Severi G; Morris HA; MacInnis RJ; English DR; Tilley WD; Hopper JL; Boyle P; Giles GG
    Cancer Epidemiol Biomarkers Prev; 2006 Jun; 15(6):1137-41. PubMed ID: 16775172
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum insulin-like growth factor-I levels and prostatic intraepithelial neoplasia: a clue to the relationship between IGF-I physiology and prostate cancer risk.
    Nam RK; Trachtenberg J; Jewett MA; Toi A; Evans A; Emami M; Narod SA; Pollak M
    Cancer Epidemiol Biomarkers Prev; 2005 May; 14(5):1270-3. PubMed ID: 15894684
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prostate cancer risk in relation to selected genetic polymorphisms in insulin-like growth factor-I, insulin-like growth factor binding protein-3, and insulin-like growth factor-I receptor.
    Chen C; Freeman R; Voigt LF; Fitzpatrick A; Plymate SR; Weiss NS
    Cancer Epidemiol Biomarkers Prev; 2006 Dec; 15(12):2461-6. PubMed ID: 17164371
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum insulin-like growth factor (IGF) and IGF-binding protein levels and risk of lung cancer: a case-control study nested in the beta-Carotene and Retinol Efficacy Trial Cohort.
    Spitz MR; Barnett MJ; Goodman GE; Thornquist MD; Wu X; Pollak M
    Cancer Epidemiol Biomarkers Prev; 2002 Nov; 11(11):1413-8. PubMed ID: 12433720
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Insulin-like growth factor-I, its binding proteins (IGFBP-1 and IGFBP-3), and growth hormone and breast cancer risk in The Nurses Health Study II.
    Schernhammer ES; Holly JM; Hunter DJ; Pollak MN; Hankinson SE
    Endocr Relat Cancer; 2006 Jun; 13(2):583-92. PubMed ID: 16728584
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Insulin-like growth factor I (IGF-I), IGF-binding proteins, and breast cancer.
    Krajcik RA; Borofsky ND; Massardo S; Orentreich N
    Cancer Epidemiol Biomarkers Prev; 2002 Dec; 11(12):1566-73. PubMed ID: 12496045
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Putative role of serum insulin-like growth factor-1 (IGF-1) and IGF binding protein-3 (IGFBP-3) levels in the development of prostate cancer in Arab men.
    Kehinde EO; Akanji AO; Mojiminiyi OA; Bashir AA; Daar AS; Varghese R
    Prostate Cancer Prostatic Dis; 2005; 8(1):84-90. PubMed ID: 15775992
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of insulin-like growth factor I and insulin-like growth factor-binding protein-3 with intelligence quotient among 8- to 9-year-old children in the Avon Longitudinal Study of Parents and Children.
    Gunnell D; Miller LL; Rogers I; Holly JM;
    Pediatrics; 2005 Nov; 116(5):e681-6. PubMed ID: 16263982
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Factors associated with circulating levels of insulin-like growth factor-I and insulin-like growth factor binding protein-3 in 740 women at risk for breast cancer.
    Johansson H; Baglietto L; Guerrieri-Gonzaga A; Bonanni B; Mariette F; Macis D; Serrano D; Sandri MT; Decensi A
    Breast Cancer Res Treat; 2004 Nov; 88(1):63-73. PubMed ID: 15538047
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A prospective study of plasma insulin-like growth factor-1 and binding protein-3 and risk of colorectal neoplasia in women.
    Giovannucci E; Pollak MN; Platz EA; Willett WC; Stampfer MJ; Majeed N; Colditz GA; Speizer FE; Hankinson SE
    Cancer Epidemiol Biomarkers Prev; 2000 Apr; 9(4):345-9. PubMed ID: 10794477
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased plasma levels of insulin-like growth factor 2 and insulin-like growth factor binding protein 3 are associated with endometrial cancer risk.
    Oh JC; Wu W; Tortolero-Luna G; Broaddus R; Gershenson DM; Burke TW; Schmandt R; Lu KH
    Cancer Epidemiol Biomarkers Prev; 2004 May; 13(5):748-52. PubMed ID: 15159305
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vitamin D receptor gene polymorphisms, insulin-like growth factors, and prostate cancer risk: a population-based case-control study in China.
    Chokkalingam AP; McGlynn KA; Gao YT; Pollak M; Deng J; Sesterhenn IA; Mostofi FK; Fraumeni JF; Hsing AW
    Cancer Res; 2001 Jun; 61(11):4333-6. PubMed ID: 11389055
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Measurement of insulin-like growth factor axis does not enhance specificity of PSA-based prostate cancer screening.
    Oliver SE; Holly J; Peters TJ; Donovan J; Persad R; Gillatt D; Pearce A; Hamdy FC; Neal DE; Gunnell D
    Urology; 2004 Aug; 64(2):317-22. PubMed ID: 15302487
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum measurements of testosterone, insulin-like growth factor 1, and insulin-like growth factor binding protein-3 in the diagnosis of prostate cancer among Korean men.
    Hong SK; Han BK; Jeong JS; Jeong SJ; Moon KH; Byun SS; Lee SE
    Asian J Androl; 2008 Mar; 10(2):207-13. PubMed ID: 18097534
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum insulin-like growth factor binding protein-3/prostate-specific antigen ratio is a useful predictive marker in patients with advanced prostate cancer.
    Miyata Y; Sakai H; Hayashi T; Kanetake H
    Prostate; 2003 Feb; 54(2):125-32. PubMed ID: 12497585
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Insulin-like growth factor-binding protein-2 in patients with prostate carcinoma and benign prostatic hyperplasia.
    Ho PJ; Baxter RC
    Clin Endocrinol (Oxf); 1997 Mar; 46(3):333-42. PubMed ID: 9156044
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.